Andarine S4 Application
Andarine is a SARM with utmost androgenic effects as it around 33% of the strength of testosterone when attaching to AR. Andarine also increases the amount of muscle mass produced by desensitizing the AR to the individual’s natural testosterone to influence a stronger effect.
Andarine is by far the most versatile SARM ever created. Not only is it the first SARM approved for a stage 2 research study, it has become the most analyzed and investigated SARM so far. After the discovery of its anabolic potential, the primary purpose of Andarine aimed to develop an alternative treatment to age-related muscle wasting, osteoporosis, and similar symptoms of hypogonadism, or end-stage renal disease.
Aside from preserving lean body mass, Andarine can also help improve it. From a stage 1 study, Andarine has provided evidence of a 3.3 lbs increase in less than 90 days with no increases exercise or change in daily diet. An unintended side effect (or benefit if you will) is the decrease in body fat. Decreases in body fat are dependent on the person’s genetics, but it will definitely have strong effects on the body’s ability to oxidize fatty tissue. Andarine was found to not only have a great affinity (potency in binding to androgen receptors), while also presenting greater anabolic effects than some traditional steroids.
Aside from its muscle building advantages, Andarine won’t cause liver damage, can prevent gynecomastia (enlarged breasts in men) and can help boost your overall health.
Andarine S4 Description
Andarine (GTx-007, S-4) is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, using the non-steroidal androgen antagonist bicalutamide as a lead compound.
Andarine is an orally active partial agonist for androgen receptors.It is less potent in both anabolic and androgenic effects than other SARMs.In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects.[3] This suggests that it is able to competitively block binding of dihydrotestosterone to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic drugs traditionally used for treatment of BPH.




Reviews
There are no reviews yet.